Skip to main navigation Skip to search Skip to main content

Non-osteoporotic post-menopausal women do not have elevated concentrations of autoantibodies against osteoprotegerin

  • Isabelle Piec
  • , Sophie Paddock
  • , Christopher Washbourne
  • , Jonathan Tang
  • , Julie Greeves
  • , Sarah Jackson
  • , Stuart Ralston
  • , Philip Riches
  • , Helen McDonald
  • , William Fraser

Research output: Contribution to conference › Poster › peer-review

28 Downloads (Pure)

Abstract

Introduction:
Osteoprotegerin (OPG) plays a protective role in bone remodelling as it provides a ‘decoy’ binding site for RANKL, preventing the stimulation of osteoclasts. Autoantibodies to OPG allow a sustained reaction between RANKL and RANK which in turn increase bone degradation. Autoantibodies against Osteoprotegerin (-OPGAb) first isolated in patients with autoimmune conditions associated with high bone turnover have been shown to be present in 14% of a healthy young adult population. Bone degradation is more prominent in the oldest population, particularly in women.
Objective:
To define a reference range for OPG autoantibodies in non-osteoporotic post-menopausal women.
Method:
Using a previously developed sandwich ELISA assay we were able to detect OPG autoantibody in serum samples taken from non-osteoporotic post-menopausal women (ANSAVID study - 60-65yrs). Briefly, -OPGAb are captured by the use of an immobilized full-length human recombinant OPG and detected by the sequential addition of a biotinylated antibody and a horseradish-peroxidase-labelled streptavidin. The concentration of human α-OPGAb in the samples is determined directly from a 4PL-fit standard curve.
Results:
We established that the population of post-menopausal women who do not present osteoporosis do not have elevated concentration of -OPGAb as compared to a younger healthy population (17-32yrs). This suggest that -OPGAb is not normally occurring with age suggesting that the production of -OPGAb is solely related to pathologic conditions in which the bone is heavily degraded.
Conclusion:
Comparison of osteoporotic patient samples to the non-osteoporotic post-menopausal women would be interesting to determine whether -OPGAb can be used to identify appropriate treatment options for this particular subgroup of patients.
Original languageEnglish
Publication statusPublished - 8 Oct 2015
EventAmerican Society for Bone and Mineral Research - Seattle, United States
Duration: 7 Oct 2015 → 12 Oct 2015

Conference

ConferenceAmerican Society for Bone and Mineral Research
Country/TerritoryUnited States
CitySeattle
Period7/10/15 → 12/10/15

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this